# Session summary: musing-murdock-c08478

**Stamp:** 2026-05-08
**Sessions span:** 2026-05-04 through 2026-05-08
**Master HEAD at session close:** `a1aecc37`
**Total PRs merged:** 18

---

## 1. What this session accomplished

Two coordinated waves landed in master:

### Wave 1: GI-2 KB content (Phase A + Phase D) — 14 PRs

Closed coverage gaps in gastric + esophageal cancer KB against ESMO 2024 / UpToDate baseline. Started at ~25% domain coverage; ended with primary-trial citations + 1L/2L metastatic indications + extended personalisation BMA + algorithm routing to all new indications.

### Wave 2: §17 schema refactor — 4 PRs (planning + lessons + implementation)

Promoted `KNOWLEDGE_SCHEMA_SPECIFICATION.md` §17 from PROPOSAL → ratified. Added Pydantic models for Surgery + RadiationCourse + IndicationPhase. Loader extended with new ref-integrity rules. 5 GI diseases re-stamped `proposal_status: full`. Unblocks Phase C of GI-2 wave (5 chunks).

---

## 2. PR ledger

| # | PR | Commit | Title |
|---|---|---|---|
| 1 | #396 | `ad90099b` | feat(kb): GI-2 W0-1 gastric primary-trial source backfill (8 sources) |
| 2 | #397 | `b6f49b26` | fix(kb): GI-2 W0-3 propagate SRC-CHECKMATE-649-JANJIGIAN-2022 citations |
| 3 | #398 | `3cac0fe8` | feat(kb): GI-2 W0-2 esophageal trial source backfill (5 sources) |
| 4 | #401 | `09359087` | fix(kb): GI-2 B1 reconcile gastric 1L PD-L1 CPS threshold + canonical CheckMate-649 nivo dose |
| 5 | #402 | `1017fe5c` | docs(plans): GI-2 wave plan + post-W0 corrections |
| 6 | #404 | `92744023` | feat(kb): GI-2 W0-4 add DESTINY-Gastric04 source (Shitara 2025) |
| 7 | #408 | `bce7a093` | feat(kb): GI-2 A1-redux esoph 1L gaps — 2 indications + 1 regimen (3rd deferred) |
| 8 | #409 | `adc07347` | feat(kb): GI-2 A2 extended personalisation — FGFR2b + EBV BMA (HER2-low deferred) |
| 9 | #414 | `397dbc0b` | feat(kb): GI-2 W0-5 EBV gastric primary sources + BMA citation upgrade |
| 10 | #416 | `0593eb5d` | feat(kb): GI-2 bemfill — REG-BEMARITUZUMAB-MFOLFOX6 + FORTITUDE-101 stub upgrade |
| 11 | #417 | `eaa2b906` | feat(kb): GI-2 A1-extension HER2+ 2L T-DXd repurpose (resolves #406) |
| 12 | #418 | `33d65f23` | docs(plans): GI-2 Phase A final outcome (§13) |
| 13 | #421 | `58c5b927` | feat(kb): GI-2 drug-stubs DRUG-BEMARITUZUMAB + DRUG-PAZOPANIB (-2 ref errors) |
| 14 | #423 | `7caae642` | feat(kb): GI-2 D1 algorithm extensions (4 routing branches, all engine-smoke green) |
| 15 | #424 | `c1e7fae8` | docs(plans): GI-2 long-tail backlog + §17 schema refactor planning |
| 16 | #426 | `4ce63e0a` | docs(plans): refactor lessons for future schema-refactor sessions |
| 17 | #427 | `9882381c` | feat(schema): §17 ratification — Surgery + RadiationCourse + Indication.phases |
| 18 | #428 | `a1aecc37` | docs(plans): refactor lessons §8 — execution findings from §17 agent |

---

## 3. Net KB additions

| Category | Count |
|---|---|
| Sources NEW | 17 |
| Sources cited (propagation) | 4 |
| Indications NEW | 4 |
| Indications EDIT | 2 |
| Regimens NEW | 2 |
| Regimens EDIT | 1 |
| BMAs NEW | 3 |
| BMA citations upgraded | 1 (EBV) |
| Biomarkers NEW | 1 |
| Drugs NEW | 2 |
| RFs EDIT | 1 |
| Algorithm routing branches NEW | 4 |
| Pydantic models NEW | 3 (Surgery, RadiationCourse, IndicationPhase) |
| Pydantic enums NEW | 4 (SurgeryIntent, RadiationIntent, IndicationPhaseStage, IndicationPhaseType) |
| Diseases re-stamped | 5 GI |
| Test files NEW | 3 + 3 fixtures |
| New tests | 28 |

---

## 4. Spec defects caught by agents

5 distinct spec defects in plans were caught by agents during execution; none made it into KB:

1. DG-04 covers HER2-low (DG-04 is HER2-positive only — caught by A1 + A2)
2. OMEC-1 paper year 2018 (paper is actually 2023 — caught by W0-2)
3. Schema fields `kind:` / `clinical_trial_registration:` invented (real schema uses `source_type:` + NCT in `notes:` — caught by W0-2 + B1)
4. Kim NatMed PMID `29983499` (real PMID `30013197` — caught by W0-5)
5. Kim paper described as KEYNOTE-012 sub-analysis (actual paper is independent Samsung phase-2 — caught by W0-5)

Patterns that drove this success:
- Mandatory schema-discovery as step 1 of every chunk-task
- Canonical-citation verification via WebFetch / NCBI E-utilities
- Hard rule "DO NOT invent fields" with free-text fallback in `notes:`
- Honest-reporting expectation in commit messages + PR bodies

---

## 5. Items deferred / parked for future sessions

### 5.1 GI-2 Phase C (unblocked by §17, ready to dispatch)

5 chunks now possible:
- C1 FLOT periop gastric
- C2 CROSS RT phasing
- C3 definitive CRT esoph SCC
- C4 MIE / RAMIE selection
- C5 OMEC oligometastatic

### 5.2 Long-tail backlog

Captured in `docs/plans/gi2_long_tail_followups_2026-05-07.md`:
- KEYNOTE-061 EBV+ subset analysis source
- Pazopanib primary RCTs (VEG105192 / PALETTE / COMPARZ)
- SRC-FORTITUDE-101 evidence_tier 2→1 upgrade when full publication lands
- DESTINY-Gastric02 watch (HER2-low Western gastric)
- Source-ID hyphenation renormalisation (#400)
- OMEC-1 year mismatch
- English-string predicates in algo_esoph_metastatic_1l
- Clinical signoff queue (CHARTER §6.1) on tier-1 BMAs

### 5.3 Future workstreams

- GI-3 wave (pancreaticobiliary + CRC expansion)
- Engine pass-through of `phases` (§17.4 step 4)
- Render phased-timeline section (§17.4 step 5)

---

## 6. Reference docs (all merged in this session)

- `docs/plans/gi2_wave_gastric_esophageal_2026-05-04-1730.md` — GI-2 plan + post-mortem (PR #402, #418)
- `docs/plans/gi2_long_tail_followups_2026-05-07.md` — long-tail backlog (PR #424)
- `docs/plans/schema_17_refactor_2026-05-07.md` — §17 schema refactor plan (PR #424)
- `docs/plans/refactor_lessons_2026-05-07.md` — lessons for future refactor sessions (PR #426 + §8 in PR #428)
- `specs/KNOWLEDGE_SCHEMA_SPECIFICATION.md` §17 — ratified (PR #427)

---

## 7. Estimate vs actual

| Metric | Original (full GI-2 wave with §17) | Actual |
|---|---|---|
| Chunks | 11-14 | 13 (Phase A+D) + 1 (§17) = 14 |
| Agent-hours | 30-65 | ~20 (synchronous gates, WebFetch lookups, 5 spec-defect resolutions) |
| PRs | 11-14 | 18 |
| Calendar-days | 6-16 | 4 (2026-05-04 → 2026-05-07) + 1 (2026-05-08 §17 + lessons) |

Significantly under estimate. 5 spec defects caught + resolved without polluting KB. Honest-reporting + schema-discovery patterns scaled cleanly across 14+ agent runs.
